Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) signed letter of intent to acquire a 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian for CNY 500 million on September 22, 2023. Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) agreed to acquire a 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian for CNY 500 million on October 16, 2023. As on October 9, 2023, shareholders approved the Proposal on the Acquisition of Equity Interests in Guizhou Hanfang Pharmaceutical.

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) completed the acquisition of 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian on October 30, 2023.